ProQR Therapeutics (PRQR) Interest Coverage Ratio (2014 - 2026)
ProQR Therapeutics (PRQR) posted Interest Coverage Ratio of 290.4 for Q1 2026, down 5323.73% sequentially from 5.35 in Q4 2025, and down 463.84% YoY from 79.82 in Q1 2025.
ProQR Therapeutics (PRQR) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
ProQR Therapeutics has reported Interest Coverage Ratio for 12 years, with the latest figure at 290.4 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 463.84% year-over-year to 290.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.0 (down 55.35% YoY) and the FY2025 annual result came in at 33.76, down 20.09% from the prior year.
- Interest Coverage Ratio eased to 290.4 in Q1 2026 per PRQR's latest filing, from 5.35 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 74.73 in Q3 2025 and troughed at 290.4 in Q1 2026.
- A 4-year average of 33.48 and a median of 5.35 in 2025 frame the typical range for Interest Coverage Ratio.
- The widest YoY moves for Interest Coverage Ratio: up 87.76% in 2025, down 1143.22% in 2025.
- Over 4 years, Interest Coverage Ratio stood at 1.71 in 2022, then sank by 252.9% to 6.02 in 2024, then climbed by 11.04% to 5.35 in 2025, then sank by 5323.73% to 290.4 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 290.4, 5.35, and 74.73 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -290.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -290.40 |
| Dec 31, 2025 | -5.35 |
| Sep 30, 2025 | 74.73 |
| Jun 30, 2025 | -235.56 |
| Mar 31, 2025 | -51.50 |
| Dec 31, 2024 | -6.02 |
| Sep 30, 2024 | 39.80 |
| Jun 30, 2024 | -18.95 |
| Mar 31, 2024 | 42.72 |
| Dec 31, 2022 | -1.71 |
| Sep 30, 2022 | 18.14 |
| Jun 30, 2022 | 12.80 |
| Mar 31, 2022 | -13.98 |
| Dec 31, 2021 | 32.39 |
| Sep 30, 2021 | 25.95 |
| Jun 30, 2021 | 22.96 |
| Mar 31, 2021 | 20.94 |
| Dec 31, 2020 | 23.06 |
| Sep 30, 2020 | 19.09 |
| Jun 30, 2020 | 98.79 |